CLINICAL_TRIALS
trial_result
· 2007-03-28
Clinical Trial Update: Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia [Phase 2]
Summary
A Phase 2 placebo-controlled dose-response trial of PD-217,014 for postherpetic neuralgia has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Pain | Phase 2 | Status: TERMINATED